Online citations, reference lists, and bibliographies.
← Back to Search

Inhibition Of The Met Receptor In Mesothelioma

T. Mukohara, Gabriel Civiello, I. Davis, M. Taffaro, J. Christensen, D. Fisher, B. Johnson, P. Jänne
Published 2005 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Background: Expression of the Met receptor and its ligand, hepatocyte growth factor (HGF), has been observed in 74% to 100% and 40% to 85% of malignant pleural mesothelioma (MPM) specimens, respectively. HGF stimulation has been shown to enhance MPM cell proliferation, migration, cell scattering, and invasiveness. Experimental Design: To investigate a potential therapeutic role for the Met receptor in MPM, we examined the effects of PHA-665752, a specific small-molecule inhibitor of the Met receptor tyrosine kinase, in a panel of 10 MPM cell lines. Results: Two of the cell lines, H2461 and JMN-1B, exhibited autocrine HGF production as measured by ELISA (3.9 and 10.5 ng/mL, respectively, versus <0.05 ng/mL in other cell lines). Evaluation of PHA-665752 across the 10 MPM cell lines indicated that despite Met expression in all cell lines, only in cell lines that exhibited a Met/HGF autocrine loop, H2461 and JMN-1B, did PHA-665752 inhibit growth with an IC50 of 1 and 2 μmol/L, respectively. No activating mutations in Met were detected in any of the cell lines. Consistent with observed growth inhibition, PHA-665752 caused cell cycle arrest at G1-S boundary accompanied by a dose-dependent decrease in phosphorylation of Met, p70S6K, Akt, and extracellular signal-regulated kinase 1/2. Growth of H2461 cells was also inhibited by neutralizing antibodies to HGF and by RNA interference knockdown of the Met receptor, confirming that growth inhibition observed was through a Met-dependent mechanism. PHA-665752 also reduced MPM in vitro cell migration and invasion. Conclusions: Taken together, these findings suggest that inhibition of the Met receptor may be an effective therapeutic strategy for patients with MPM and provides a mechanism, the presence of a HGF/Met autocrine loop, by which to select patients for PHA-665752 treatment.
This paper references
10.1038/sj.onc.1203557
Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells
Michal Firon (2000)
10.1093/CARCIN/23.6.1017
Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma.
G. Gordon (2002)
10.1016/S1359-6101(01)00029-6
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
G. Maulik (2002)
Somatic mutations of the METoncogene are selected during metastatic spread of humanHNSC carcinomas
MF DiRenzo (2000)
Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.
G. Shapiro (1999)
Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor-like substance.
J. Klominek (1993)
10.1615/CRITREVONCOG.V8.I4.40
Role of focal adhesion proteins in signal transduction and oncogenesis.
E. Weisberg (1997)
10.3816/CLC.2003.N.023
Chemotherapy for malignant pleural mesothelioma.
P. Jänne (2003)
10.1038/sj.onc.1201905
Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering
S. Tanimura (1998)
10.1038/bjc.1996.64
Hepatocyte growth factor/scatter factor is present in most pleural effusion fluids from cancer patients.
G. Eagles (1996)
10.1038/sj.onc.1207691
The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants
Sylvie Berthou (2004)
10.1007/s004320050171
Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma
E. Tolnay (1998)
10.1074/jbc.M107551200
Hepatocyte Growth Factor Induces ERK-dependent Paxillin Phosphorylation and Regulates Paxillin-Focal Adhesion Kinase Association*
Zhenxiang Liu (2002)
10.1046/J.1365-2559.2000.00888.X
Immunoreactivity for cadherins, HGF/SF, met, and erbB‐2 in pleural malignant mesotheliomas
I. Thirkettle (2000)
10.1182/BLOOD.V74.3.940.BLOODJOURNAL743940
Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro.
G. Demetri (1989)
10.1074/jbc.274.23.16377
Activation Mechanisms of the Urokinase-type Plasminogen Activator Promoter by Hepatocyte Growth Factor/Scatter Factor*
S. Ried (1999)
10.1073/pnas.211026798
SV40 replication in human mesothelial cells induces HGF/Met receptor activation: A model for viral-related carcinogenesis of human malignant mesothelioma
P. Cacciotti (2001)
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas.
W. Park (1999)
10.1038/sj.onc.1202547
Novel mutations of the MET proto-oncogene in papillary renal carcinomas
Laura Schmidt (1999)
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
J. Christensen (2003)
Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion.
G. Davies (2001)
10.1038/bjc.1998.176
Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology.
P. Harvey (1998)
Gefitinib in patients with malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30101)
R Govindan (2003)
10.1111/J.1432-0436.1988.TB00806.X
Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines.
G. Bepler (1988)
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
P. Jänne (2002)
10.1016/J.MOLCEL.2004.10.006
Paxillin serves as an ERK-regulated scaffold for coordinating FAK and Rac activation in epithelial morphogenesis.
Shuta Ishibe (2004)
10.1007/BF02306613
Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
H. Pass (2006)
10.1172/JCI15418
Dysregulation of Met receptor tyrosine kinase activity in invasive tumors.
Alla Danilkovitch-Miagkova (2002)
10.1016/0003-4975(95)00045-M
Characteristics of nine newly derived mesothelioma cell lines.
H. Pass (1995)
10.1159/000086994
Therapeutic Targeting of Multiple Signaling Pathways in Malignant Pleural Mesothelioma
T. Mukohara (2005)
10.1016/S1097-2765(01)00378-1
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.
P. Peschard (2001)
Advances in Brief Gefitinib Induces Apoptosis in the EGFRL 858 R Non – Small-Cell Lung Cancer Cell Line H 3255
S. Tracy (2004)
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
P. Ma (2003)
Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma.
Maria E. Ramos-Nino (2003)
10.1074/JBC.M403954200
A Conserved DpYR Motif in the Juxtamembrane Domain of the Met Receptor Family Forms an Atypical c-Cbl/Cbl-b Tyrosine Kinase Binding Domain Binding Site Required for Suppression of Oncogenic Activation*
P. Peschard (2004)
in papillary renal carcinomas
S Berthou (1999)
Alteration of Met protooncogene product expression and prognosis in breast carcinomas.
I. Tsarfaty (1999)
10.1054/bjoc.2000.1445
Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases
P. Harvey (2000)
10.1158/0008-5472.CAN-04-1905
Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
S. Tracy (2004)
Func - tional expression and mutations of c - Met and its therapeutic inhibition with SU 11274 and small interfering RNA in non - small cell lung cancer
JagadeeswaranR MaPC (2005)
10.1002/path.824
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)
10.1073/PNAS.95.24.14417
The mutationally activated Met receptor mediates motility and metastasis.
M. Jeffers (1998)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1038/NG0597-68
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
L. Schmidt (1997)
10.1038/sj.onc.1203455
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
M. D. Renzo (2000)
10.1002/(SICI)1096-9896(199612)180:4<389::AID-PATH685>3.0.CO;2-K
IMMUNOREACTIVITY FOR HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR AND ITS RECEPTOR, met, IN HUMAN LUNG CARCINOMAS AND MALIGNANT MESOTHELIOMAS
P. Harvey (1996)
10.1002/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G
Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c‐met receptor
J. Klominek (1998)
10.1016/S0022-5223(19)36577-8
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
10.1053/HUPA.2001.21133
Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer.
M. Tsao (2001)
10.1038/sj.onc.1203874
A novel germ line juxtamembrane Met mutation in human gastric cancer
J. Lee (2000)
10.1158/0008-5472.CAN-04-2650
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
P. Ma (2005)
10.1126/SCIENCE.1846706
Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.
D. Bottaro (1991)
Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma.
C. Qian (2002)
10.1038/bjc.1990.207
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody.
H. Dazzi (1990)
Ther - apeutic targetingofmultiple signalingpathways inma - lignant pleural mesothelioma
MukoharaT (2005)
Phase III study of pemetrexed in combinationwith cisplatin versus cisplatin alone in patients with malignant pleuralmesothelioma
NJ Vogelzang (2003)
An epithelial scatter factor released by embryo fibroblasts.
M. Stoker (1985)
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
G. Maulik (2002)
Hepatocyte growth factor / scatter factor and its receptor c - Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelio
E Tolnay (1998)
Chemotherapy formalignant pleuralmesothelioma
PA Janne (2003)
10.1200/JCO.2004.22.90140.3007
Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM).
L. Garland (2004)
10.6004/JNCCN.2012.0006
[Malignant pleural mesothelioma].
Q. Kong (1983)



This paper is referenced by
10.1016/j.lungcan.2008.06.011
MET as a target for treatment of chest tumors.
N. Cipriani (2009)
10.1016/j.humpath.2020.08.010
c-MET Immunohistochemistry For Differentiating Malignant Mesothelioma from Benign Mesothelial Proliferations.
Hezhen Ren (2020)
10.1593/NEO.06499
Inhibition of c-Met as a Therapeutic Strategy for Esophageal Adenocarcinoma
G. Watson (2006)
10.1038/ncponc1039
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
10.1016/j.canlet.2009.02.056
Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
T. Mukohara (2009)
c-Met Axis − miR-34 a − Mesotheliomas with Enriched Cancer Stem Cells via a p 53 Tumor Suppressor Alterations Cooperate to Drive Aggressive
Craig W. Menges (2014)
10.1371/journal.pone.0036856
Perifosine as a Potential Novel Anti-Cancer Agent Inhibits EGFR/MET-AKT Axis in Malignant Pleural Mesothelioma
G. Pinton (2012)
Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.
N. Nasreen (2012)
10.1038/cdd.2009.32
Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates
J. Daubriac (2009)
10.3978/j.issn.2072-1439.2013.08.08
Malignant pleural mesothelioma: current and future perspectives.
Konstantinos Porpodis (2013)
10.1097/mot.0b013e328011d897
Current World Literature
(2006)
10.3978/j.issn.2072-1439.2015.02.19
Pleural mesothelial cells in pleural and lung diseases.
H. Batra (2015)
10.1158/1078-0432.CCR-08-0071
Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer
L. Toschi (2008)
Human papillomavirus type 16 E 6 suppresses microRNA-23 b expression in human cervical cancer cells through DNA methylation of the host gene C 9 orf 3
C. A. Yeung (2017)
10.1165/RCMB.2007-0206OC
HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway.
Maria E. Ramos-Nino (2008)
10.1007/s10637-013-9959-2
Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line
Y. Funakoshi (2013)
10.3892/ijo.2017.4021
DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma
H. Wang (2017)
10.1002/hed.20816
Small molecule c‐MET inhibitor PHA665752: Effect on cell growth and motility in papillary thyroid carcinoma
Chandrani Chattopadhyay (2008)
10.3390/biomedicines2040327
HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis
G. Gaudino (2014)
10.1007/978-3-642-10862-4_9
Genetics and molecular biology of mesothelioma.
D. Fennell (2011)
Single-Agent and CombinationTherapeutic Strategies to Inhibit Hepatocyte Growth Factor / MET Signaling in Cancer
LucaToschi (2008)
10.1093/carcin/bgp097
Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
K. Kawaguchi (2009)
10.1016/j.omtn.2019.05.017
Anticancer Drug Response Prediction in Cell Lines Using Weighted Graph Regularized Matrix Factorization
Na-Na Guan (2019)
10.1593/NEO.101156
Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.
W. Ou (2011)
10.1038/onc.2010.555
AXL regulates mesothelioma proliferation and invasiveness
W. Ou (2011)
10.1038/bjc.2014.220
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
S. Zhou (2014)
10.1158/0008-5472.CAN-13-2062
Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.
C. Menges (2014)
10.1593/TLO.08133
Proteasome Inhibitor MG132 Induces Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells.
Bao-Zhu Yuan (2008)
10.1016/j.ajpath.2011.08.007
Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma.
S. Uddin (2011)
10.1042/BST20150252
The role of the HGF/Met axis in mesothelioma.
Thivyan Thayaparan (2016)
10.1007/s11095-007-9316-2
Pharmacokinetics and Safety of a Fully Human Hepatocyte Growth Factor Antibody, AMG 102, in Cynomolgus Monkeys
T. Kakkar (2007)
10.1016/j.molonc.2015.05.007
Inhibition of ligand‐independent constitutive activation of the Met oncogenic receptor by the engineered chemically‐modified antibody DN30
E. Vigna (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar